ViiV Buys Promising New Mechanisms In HIV From BMS

GlaxoSmithKline PLC's majority-owned ViiV Healthcare is buying a raft of novel late-stage and early stage HIV assets from Bristol-Myers Squibb Co which it hopes will offer new options for patients who have outlived the utility of other antiretrovirals, thereby expanding ViiV's pipeline and future product sales.